Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Phio Pharmaceuticals Corp. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 12 | 8 | −4 |
| Shares | 575.3K | 39.1K | −536.1K (−93.2%) |
| Value | $213.2K | $219.7K | +$6.50K (+3.1%) |
New holders (1)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 14,233 | $80.0K | 0.00% |
Sold out (5)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Geode Capital Management, LLC | 106,917 | $39.0K |
| Cetera Investment Advisers | 75,000 | $27.9K |
| Two Sigma Investments, LP | 22,398 | $8.33K |
| Two Sigma Securities, LLC | 19,707 | $7.33K |
| Tower Research Capital LLC (TRC) | 5,220 | $2.00K |